Oric Pharmaceuticals (ORIC) Director Richard Heyman Sells 300 Shares

What Happened Richard A. Heyman, a director of Oric Pharmaceuticals, reported the sale of 300 shares on July 6, 2026. The shares were disposed at $12.00 each for a total value of $3,600. The filing shows the sale was made pursuant to a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date and price: 2026-07-06, 300 shares sold at $12.00 per share.
• Total proceeds: $3,600.
• Shares held/ownership: Shares are held of record by RAHD Capital, LLC; Heyman has voting and investment power over those shares (no post-transaction total reported on this Form 4).
• Footnotes: F1 — sale effected under a Rule 10b5-1 plan; F2 — shares held by RAHD Capital, LLC with Heyman having voting/investment power.
• Filing timing: Form was filed 2026-07-08 for a 2026-07-06 transaction — appears to be filed within the usual two-business-day window.

Context This was a sale (disposition), not a purchase or option exercise. Sales under 10b5-1 plans are typically prearranged and considered routine; they do not necessarily indicate a change in the director’s view of the company.